Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growth SYMBRAVO® 3Q 2026 net product sales of $3.9 million, representing 88% year-over-year growth • Total net product revenue was $2 ...